Endoxifen

CAS No. 112093-28-4

Endoxifen( —— )

Catalog No. M10432 CAS No. 112093-28-4

A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 73 In Stock
5MG 120 In Stock
10MG 192 In Stock
25MG 356 In Stock
50MG 555 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Endoxifen
  • Note
    Research use only, not for human use.
  • Brief Description
    A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer.
  • Description
    A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer.Breast Cancer Phase 1 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER|ERR|hERGPotassiumChannel
  • Research Area
    Cancer
  • Indication
    Breast Cancer

Chemical Information

  • CAS Number
    112093-28-4
  • Formula Weight
    373.4874
  • Molecular Formula
    C25H27NO2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3
  • Chemical Name
    Phenol, 4-[(1Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Brauch H, et al. Clin Chem. 2009 Oct;55(10):1770-82. 2. Markopoulos C, et al. World J Clin Oncol. 2014 Aug 10;5(3):374-81. 3. Mugundu GM, et al. Drug Metab Dispos. 2012 Feb;40(2):389-96.
molnova catalog
related products
  • SNG-1153

    A derivate of icaritin that inhibits the growth of lung CSCs.

  • Fulvestrant

    Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast Y in post-menopausal women with disease progression following anti-estrogen therapy.

  • LY500307

    LY500307 (LY-500307, Erteberel, SERBA-1) is a potent, selective Estrogen Receptor β (ERβ) agonist with Ki/EC50 of 0.19/0.66 nM.